Neuroprotective effects of pifithrin-α against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis

Ya-Ni Huang1,2, Ling-Yu Yang2, Nigel H. Greig3, Yu-Chio Wang2,4, Chien-Cheng Lai5 & Jia-Yi Wang2,6

Cortical and hippocampal neuronal damages caused by traumatic brain injury (TBI) are associated with motor and cognitive impairments; however, only little attention paid to the striatal damage. It is known that the p53 tumor-suppressor transcription factor participated in TBI-induced secondary brain damage. We investigated how the p53 inactivator pifithrin (PFT)-α affected TBI-induced striatal neuronal damage at 24 h post-injury. Sprague-Dawley rats subjected to a controlled cortical impact were used as TBI models. We observed that p53 mRNA significantly increased, whereas p53 protein expression was distributed predominantly in neurons but not in glia cells in striatum after TBI. PFT-α improved motor deficit following TBI. PFT-α suppressed TBI-induced striatal glial activation and expression of proinflammatory cytokines. PFT-α alleviated TBI-induced oxidative damage TBI induced autophagy was evidenced by increased protein expression of Beclin-1 and shift of microtubule-associated light chain (LC)3-I to LC3-II, and decreased p62. These effects were reduced by PFT-α. Post-injury PFT-α treatment reduced the number of degenerating (FJC-positive) and apoptotic neurons. Our results suggest that PFT-α may provide neuroprotective effects via p53-dependent or -independent mechanisms depending on the cell type and timing after the TBI and can possibly be developed into a novel therapy to ameliorate TBI-induced neuronal damage.

Traumatic brain injuries (TBIs) are a serious health problem worldwide. TBIs range from mild to severe, and most victims of TBI have mild injury characterized by short- and long-term physical, emotional, behavioral, and cognitive impairments consequent to the brain damage. It is becoming increasingly evident that dysregulation of the dopamine (DA) system may be a major contributing mechanism for behavioral and cognitive deficits after TBI. Reductions in striatal tyrosine hydroxylase activity and DA release in the striatum of rats were reported after TBI. TBI-induced striatal mitochondrial disruption causes behavioral deficits. Those findings suggest that loss of function of the striatal DA system and/or striatal damage after TBI may be major contributing mechanisms for behavioral impairments. However, the underlying cellular and molecular mechanisms still need to be further explored.

1Department of Nursing and Department of Optometry, Hsin Sheng Junior College of Medical Care and Management, Taoyuan City, Taiwan. 2Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan. 3Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. 4School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 5Division of Orthopedics, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan. 6Department of Physiology, College of Medicine, Taipei Medical University, Taipei, Taiwan. Correspondence and requests for materials should be addressed to J.-Y.W. (email: jywang2010@tmu.edu.tw)
The TBI mechanism is a complicated pathological process that consists of a primary insult (mechanical impact) and secondary (delayed) insults. Hallmarks of the secondary insult response in TBIs include generation of neuroinflammation, reactive oxygen species (ROS), autophagy and apoptotic signaling cascades, all of which occur immediately following the primary mechanical insult. Evidence strongly suggests that the generation of ROS is an early event following brain injury, that occurs within minutes of a mechanical impact. When cellular damage is sufficiently profound, proapoptotic proteins (e.g., Bax and cleaved caspase-3) and transcription factors (nuclear factor (NF)-κB and p53) initiate the process of neuronal cell death. p53, a tumor-suppressor gene, is critical for activating expression of genes engaged in promoting cell-cycle arrest or cell death in response to various cellular stresses. p53’s activity is controlled by transcriptional, translational, and post-translational regulatory mechanisms. In response to cellular stress, p53 induces its biological response through the transcriptional transactivation of specific target genes such as the proapoptotic genes, Bax and PUMA. Inappropriate p53 activation is involved in stress-induced apoptotic signaling pathways in neuronal diseases and brain injuries. It was demonstrated that p53-induced apoptosis plays a crucial role in the development of hypoxic-ischemic brain damage. Inhibition of the p53 pathway improves functional outcomes and attenuates lesion volumes after hypoxia-ischemia in the rat brain. Accumulating evidence also indicates a primary role of p53 in neuronal death that occurs following TBI. Activation of c-Jun N-terminal kinase (JNK) signaling was shown to mediate neuronal cell damage after TBI. It is known that p53 is a downstream JNK signaling. The damage-regulated autophagy modulator (DRAM), a p53 target gene, is involved in autophagy formation. DRAM is involved in regulating nucleoside analog-induced neuronal autophagy in a p53-independent manner. However, p53 phosphorylation after a TBI enhances neuron autophagy through upregulating DRAM and disruption of Beclin-1 complex p53 signaling in neuronal apoptosis and autophagy formation as reported by Hong et al., also suggesting a p53-dependent pathway.

Autophagy, a lysosomal pathway for degrading and recycling macromolecules and organelles, plays an essential role in differentiation, development, and cellular homeostatic functions. ROS are essential for inducing autophagy formation. In the absence of tight regulation, autophagy accelerates the apoptotic destruction of cells via self-digestion, thus leading to cell damage. Autophagy is involved in type II (autophagic) cell death, and is distinguished from type I (apoptotic) cell death. The appearance of autophagic cell death is characterized by autophagy formation. In the absence of tight regulation, autophagy accelerates the apoptotic destruction of cells. Microtubule-associated light chain 3 (LC3) is an essential autophagy marker. The mammalian homologue of Atg6, also called Beclin-1, is essential for autophagy formation. Beclin-1 is essential for initiating autophagy via its interaction with class III phosphatidylinositol-3 (PI3) kinase. Antiautophagic proteins (e.g., Bcl2 and Bcl-xL) can bind to Beclin-1 and reduce the PI3 kinase activity associated with Beclin-1, thus inhibiting autophagy formation. In a murine encephalitis model, Beclin-1 interacted with Bcl-2 to protect neuronal cells against virus-induced cell death. Dissociation of the Bcl-/Beclin-1 complex was observed in methamphetamine-induced autophagy, thus leading to cell death. Those findings suggest that interactions between antiautophagic and autophagic proteins play important roles in cytoprotection and/or cell death.

Pifithrin (PFT)-α, a p53 inhibitor, was found to prevent neuronal cell death by inhibiting p53 transcriptional activity, mitochondrial damage, and caspase activation. PFT-α was demonstrated to be effective in preventing neuronal cell death in models of ischemia, excitotoxic insults, and Parkinson’s disease. Those results indicated that inhibition of p53 by PFT-α may prove to be a useful tool to evaluate p53-dependent cascades and may also be developed into a novel therapeutic strategy for TBIs. In the present study, we focused on effects of PFT-α in neuroinflammation, oxidative stress, autophagy, and apoptotic cell death in rats following experimental administration of TBI.

Results

Post-injury PFT-α treatment inhibits the transcriptional and translational expression of p53 in neurons at 24 h after TBI. According to our experimental design (Fig. 1), we first examined the effects of PFT-α on p53 mRNA and protein expression in striatal tissues at 24 h after TBI respectively using RT-PCR and immunofluorescence staining. Results showed that levels of p53 mRNA were significantly elevated in the

| Animal grouping | Morphological analysis | Biochemical analysis |
|-----------------|-----------------------|---------------------|
| Sham (No injury) | | |
| (1) Sham + Veh (10% DMSO in saline) | ◆ FJC, HE, DAPI staining | ◆ RT-PCR for mRNA expression |
| (2) Sham + PFT-α (2mg/kg, i.v.) | ◆ Immunofluorescence staining | ◆ Western blotting for protein expression |
| TBI | | |
| (3) TBI + Veh | | |
| (4) TBI + PFT-α | | |

Figure 1. Experimental design. Anesthetized male SD rats were subjected to either TBI with a control cortical impactor (CCI) at a velocity of 4 m/s and a deformation depth of 2 mm below the dura) or a sham procedure (craniotomy without CCI) and an iv. injection of either pifithrin (PFT)-α (2 mg/kg) or a vehicle (Veh; 10% DMSO in saline) were administered 5 h later. Animals were sacrificed at 24 h. Tissue sections were fixed and sectioned for morphological analyses (e.g., H&E, DAPI, FJC and immunofluorescence staining) and striatal tissues were isolated for biochemical analyses (measurement of mRNA and protein levels).
TBI-treated group (2.0 ± 0.23-fold, P < 0.001) compared to the sham-treated group (1 ± 0.06-fold); however, this effect was significantly attenuated in the PFT-α treatment group (0.61 ± 0.05-fold, P < 0.001) when PFT-α was administered 5 h following the TBI (Fig. 2A). Levels of p53 expression in the Sham + PFT-α group (1 ± 0.06-fold) did not significantly differ from those observed in the Sham + Veh group (1 ± 0.06-fold). Results show that levels of p53 mRNA expression in TBI + PFT-α group were significantly lower than those observed in Sham + Veh group (0.61 ± 0.05-fold vs. 1 ± 0.06-fold, P < 0.05) but were not significantly different from Sham + PFT-α group (P = 0.053). Double immunofluorescence staining was carried out on coronal sections of the dorsal striatum (Fig. 2B) from TBI + Veh animals using an antibody against p53 combined with either GFAP (a maker for astrocytes) or Iba1 (a marker for microglia). Results showed that p53 is not colocalized with GFAP (c), or Iba1 (f), but is colocalized with LC3 (i) in striatal tissues from TBI + Veh animals. Inset, a high-power image showing colocalization of p53 and LC3. Scale bar = 50 µm. (D) Double immunofluorescence staining of NeuN and p53 in striatal brain tissues. NeuN is shown in red, and p53 is shown in green. Yellow labeling indicates colocalization. (E) Quantitative comparison of NeuN-p53-positive cells in the Sham + Veh, TBI + Veh, and TBI + PFT-α groups. Data are expressed as the mean ± SD (n = 5 per group). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. Sham + Veh group; ++ P < 0.01 and +++ P < 0.001 vs. TBI + Veh group.

Figure 2. Post-injury administration of pifithrin (PFT)-α at 5 h after a traumatic brain injury (TBI) reduced levels of p53 mRNA expression and the number of p53-positive neurons in striatal tissues at 24 h. (A) mRNA levels of p53 in striatal tissues from the Sham + vehicle (Veh), Sham + PFT-α, TBI + Veh, and TBI + PFT-α groups were analyzed by an RT-PCR. Multiples of change are relative to that of the sham group. (B) A lower magnification H&E-stained coronal brain section from the TBI + Veh animal showing the dorsal striatum where the higher magnification images are taken. (C) Photomicrographs showing the results of immunofluorescence staining using anti-GFAP (a maker for astrocytes, green in a), anti-Iba1 (a maker for microglia, green in d), or LC3 (a maker for autophagy, green in g) combined with anti-p53 (red in b, e and h). Merged images show that p53 is not colocalized with GFAP (c), or Iba1 (f), but is colocalized with LC3 (i) in striatal tissues from TBI + Veh animals. Inset, a high-power image showing colocalization of p53 and LC3. Scale bar = 50 µm. (D) Double immunofluorescence staining of NeuN and p53 in striatal brain tissues. NeuN is shown in red, and p53 is shown in green. Yellow labeling indicates colocalization. (E) Quantitative comparison of NeuN-p53-positive cells in the Sham + Veh, TBI + Veh, and TBI + PFT-α groups. Data are expressed as the mean ± SD (n = 5 per group). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. Sham + Veh group; ++ P < 0.01 and +++ P < 0.001 vs. TBI + Veh group.

Post-injury treatment with PFT-α at 5 h improved neurological functional deficits after TBI.

Baseline values in all tests did not significantly differ in the Sham + Veh, Sham + PFT-α, TBI + Veh, and TBI + PFT-α groups (data not shown). Motor coordination impairment, measured by a beam walking test, was evident after a TBI in vehicle-treated animals at 24 h (Fig. 3A); however, post-injury treatment with PFT-α
caused no differences in the beam walking test compared to the TBI + Veh group. The functional evaluation measured by the elevated body swing test (EBST) at 24 h after a TBI in sham and TBI rats indicated that impaired functional outcomes, as measured by motor asymmetry, caused by the TBI were evident in the vehicle-treated group (Fig. 3B). Post-injury treatment with PFT-α slightly but not significantly improved functional deficits after the TBI, as revealed by swing tests (Fig. 3B). Functional evaluation measured by tactile adhesive removal at 24 h after the TBI in sham and TBI rats indicated that functional deficits caused by the TBI were evident in the vehicle-treated group (Fig. 3C), in which a unilateral TBI resulted in a delay in the time needed to remove the patch. Post-injury treatment with PFT-α improved the functional deficits after the TBI, as revealed by the tactile adhesive removal test (Fig. 3C, P < 0.01). In addition, neurological function as measured by mNSS scores at 24 h after the TBI in sham and TBI rats indicated that the overall functional outcome caused by the TBI was impaired in the vehicle-treated group. Post-injury treatment with PFT-α significantly improved functional deficits after the TBI, as revealed by mNSS scores (Fig. 3D; P < 0.001). All tests in Sham + PFT-α animals revealed no significant difference from those observed in Sham + Veh animals.

**Post-injury PFT-α treatment inhibits glial cell activation.** IHC staining showed that astrocytes that exhibited GFAP immunoreactivity displayed a polygonal profile, with filament-like immunoreactivity in the cytoplasm of the sham group (Fig. 4a) vs. stellate soma and hypertrophic processes, typical morphological characteristics of activated astrocytes, in the TBI + Veh group (Fig. 4b). Expression of activated microglia was negligible in the Sham + Veh group (Fig. 4d), whereas ED-1-positive cells from the TBI + Veh group had an amoeboid morphology that is characteristic of reactive microglia (Fig. 4e). However, both astrocyte and microglia activation was attenuated by PFT-α treatment (Fig. 4c,f, respectively).

**Post-injury PFT-α treatment reduces transcriptional and translational levels of TNF-α, IL-1β, and IL-6.** We examined the effects of PFT-α on TNF-α, IL-1β, and IL-6 mRNA and protein expression in striatal tissues at 24 h after TBI respectively using RT-PCR and ELISA assays. Results showed that levels of TNF-α (3.71 ± 0.78-fold, P < 0.001), IL-1β (5.53 ± 2.31-fold, P < 0.05), and IL-6 (7.5 ± 2.53-fold, P < 0.01) mRNAs were significantly elevated in the TBI-treated group compared to the sham-treated group (1 ± 0.1-fold, 1 ± 0.14-fold,

---

**Figure 3.** Post-injury administration of PFT-α at 5 h improved neurological functional outcomes as revealed by behavioral evaluation. (A) Motor coordination measured by beam walk test. (B) Motor asymmetry measured by elevated body swing test (EBST). (C) Sensory-motor function measured by adhesive removal test. (D) Neurological function measured by mNSS. Data represent the mean ± SEM (n = 4 per group). *P < 0.05 and ***P < 0.01 vs. Sham + Veh group; +++P < 0.001 vs. TBI + Veh group.
Figure 4. Post-injury administration of pifithrin (PFT)-α at 5h after a traumatic brain injury (TBI) alleviated glial activation in the striatum of TBI rats. Representative photomicrographs show brain sections from the Sham + Veh (a,d), TBI + Veh (b,e), and TBI + PFT-α (c,f) groups stained with antibodies to identify astrocytes (GFAP-positive cells; a–c) and microglia (ED1-positive cells; d–f).

and 1 ± 0.1-fold, respectively); however, this effect was significantly attenuated in the PFT-α treatment group (1.91 ± 0.16-fold, P < 0.01; 1.96 ± 0.42-fold, P < 0.05; and 1 ± 0.14-fold, P < 0.01, respectively) when administered 5h following the TBI (Fig. 5A). Levels of TNF-α, IL-1β, and IL-6 mRNAs in the Sham + PFT-α group (0.76 ± 0.07-fold, 0.63 ± 0.09-fold, and 1.28 ± 0.1-fold, respectively) did not significantly differ from those observed in the sham group (Fig. 5A). Regarding protein expression, levels of TNF-α (13 ± 0.19 pg/mg protein, P < 0.05), IL-1β (30.48 ± 1.27 pg/mg protein, P < 0.001), and IL-6 (36.56 ± 1.56 pg/mg protein, P < 0.05) protein had significantly increased in the TBI-treated group, whereas these effects were significantly reduced by PFT-α treatment (8.52 ± 0.39 pg/mg protein, P < 0.05; 21.96 ± 1.81 pg/mg protein, P < 0.001; and 26.67 ± 1.55 pg/mg protein, P < 0.01, respectively) (Fig. 5B).

Post-injury PFT-α treatment induces HO-1 expression and attenuates lipid peroxidation (LP) in the striatum of rats with TBI. Oxidative stress is a key mediator exacerbating neuronal damage and contributing to the pathogenesis of TBIs36–37. HO-1 is well known as the 32-kDa heat shock protein which is upregulated by oxidative stress and appears to be a component of the cellular oxidative stress response38–40. Double immunofluorescent staining using anti-GFAP or anti-ED1 and anti-4-HNE antibodies showed that TBI-induced 4-HNE-positive cells were not expressed by GFAP-positive astrocytes or ED1-positive microglia (Fig. 6A). Results showed that HO-1 mRNA (Fig. 6A) and protein levels (Fig. 6B) were significantly elevated in the TBI + Veh-treated group (3.07 ± 0.95-fold and 2.24 ± 0.09-fold, respectively) compared to the Sham + Veh group (1.00 ± 0.15-fold and 1.00 ± 0.09-fold, respectively), these effects were significantly enhanced in the TBI + PFT-α-treated group (7.04 ± 1.52-fold, P < 0.05; and 4.42 ± 0.96, P < 0.05, respectively). These results indicate that TBI-induced HO-1 expression is dependent on p53. However, PFT-α itself induced neither HO-1 transcription nor its translation, and therefore was p53 independent. Since HO-1 mediates cellular responses to oxidative stress and autophagy, we further examined the effect of PFT-α on oxidative stress induced by the TBI. The expression of lipid peroxidation marker (4-HNE)-positive neurons in the striatum was assessed by immunofluorescence staining. Double immunofluorescence staining using an antibody against 4-HNE combined with a NeuN antibody showed that 4-HNE-positive neuron expression in the sham group was negligible (Fig. 7Aa–d). In the TBI-treated group, 4HNE-positive neurons had significantly increased (Fig. 6Ae–h), whereas this effect was reduced by PFT-α treatment (Fig. 7Ai–l). A quantitative analysis revealed that numbers of 4-HNE-positive neurons had significantly increased at 24h in the TBI-treated group after injury (64.4% ± 4%; P < 0.001) compared to the Sham group (0.7% ± 0.7%). PFT-α administration reduced the number of 4-HNE-positive neurons (27.8% ± 6.4%; P < 0.01) compared to the TBI-treated group (Fig. 7B). However, double immunofluorescent staining using anti-GFAP or anti-ED1 and anti-4-HNE antibodies showed that TBI-induced 4-HNE-positive cells were not expressed by GFAP-positive astrocytes or ED1-positive microglia (Fig. 7C). This result suggests that TBI-induced lipid peroxidation occurred mainly in neurons.

Post-injury PFT-α treatment attenuates expression levels of autophagic markers in the striatum of rats with TBI. Increasing evidence has demonstrated that perturbation of the autophagy pathway is associated with neuronal damage after TBI41,42. To investigate the effect of PFT-α on TBI-induced autophagy, expression levels of three autophagic markers (Beclin-1, LC3II, and p62) were assessed by Western blotting. Expression levels of Beclin-1 increased after injury compared to the Sham + Veh group (1.6 ± 0.11- vs.1.00 ± 0.07-fold, P < 0.05), whereas this effect was reduced by PFT-α treatment (0.86 ± 0.18- vs. 1.6 ± 0.11-fold, P < 0.01) (Fig. 8A). In the TBI + Veh group, the LC3II had significantly increased compared to the Sham + Veh group (2.55 ± 0.48- vs. 1.00 ± 0.01-fold, P < 0.001) (Fig. 8B). Post-injury treatment with PFT-α significantly reduced LC3II expression (0.93 ± 0.026- vs. 2.55 ± 0.48-fold, P < 0.01) (Fig. 8B). In addition, p62 protein levels were significantly lower in the TBI + Veh group compared to the Sham + Veh group (0.55 ± 0.13- vs.
Post-injury administration of pifithrin (PFT)-α at 5 h after a traumatic brain injury (TBI) reduced the proinflammatory cytokine tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 levels in striatal tissues at 24 h. (A) mRNA levels of TNF-α, IL-1β, and IL-6 in brain tissues from Sham + Veh, Sham + PFT-α, TBI + Veh, and TBI + PFT-α groups were analyzed by an RT-PCR. Multiples of change are relative to that of the Sham + Veh group. (B) Levels of TNF-α, IL-1β, and IL-6 in brain tissues from Sham + Veh, Sham + PFT-α, TBI + Veh, and TBI + PFT-α groups were measured by an ELISA. Data are expressed as the mean ± SD (n = 5 per group). *P < 0.05, **P < 0.01, and ***P < 0.001 vs. Sham + Veh group; †P < 0.05, ††P < 0.01, and †††P < 0.001 vs. TBI + Veh group.

**Figure 5.** Post-injury administration of pifithrin (PFT)-α at 5 h after a traumatic brain injury (TBI) reduced the proinflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 levels in striatal tissues at 24 h.

**Post-injury PFT-α treatment reduces TBI-induced neurodegeneration.** Significant levels of apoptosis occur in the injured striatum after TBI. As illustrated in Fig. 9Ab, numerous FJC-positive cells were observed in the striatum at 24 h post-injury. A quantitative summary of FJC-positive cells observed in the Sham + Veh, TBI + Veh, and TBI + PFT-α groups is provided in Fig. 9B. Numbers of degenerating neurons were significantly elevated in the TBI + Veh group (177.9 ± 14.29/mm², P < 0.01) compared to the sham group (12.167 ± 3.07/mm²). In comparison, the PFT-α-treated TBI group had a significantly lower number of degenerating neurons (82.73 ± 3.07/mm², P < 0.05) compared to the TBI + Veh group.

**Post-injury PFT-α treatment attenuates expression of apoptotic-related genes and proteins in the striatum of rats with TBI.** To investigate the effect of PFT-α on TBI-induced apoptosis, expression levels of Bax and caspase-3 mRNAs and proteins were respectively examined by an RT-PCR and Western blotting. Levels of Bax and caspase-3 mRNAs in the Sham + PFT-α group did not significantly differ from those observed in the Sham + Veh group (Fig. 10A). Results showed that Bax and caspase-3 mRNA levels were significantly elevated in the TBI-treated group (1.49 ± 0.17-fold, P < 0.05 and 1.47 ± 0.21-fold, P < 0.01, respectively) compared to the sham-treated group (1. ± 0.11-fold and 1 ± 0.09-fold, respectively), whereas these effects were attenuated in the PFT-α-treated group (0.64 ± 0.05-fold, P < 0.001 and 0.61 ± 0.18, P < 0.05, respectively) (Fig. 10A). Levels of Bax and cleaved-caspase-3 proteins had significantly increased in the TBI-treated group (1.87 ± 0.15-fold, P < 0.05 and 4.68 ± 1.26-fold, P < 0.05, respectively; Fig. 10B), however both Bax and cleaved-caspase-3 expression were significantly reduced in the PFT-α treatment group (0.86 ± 0.29-fold, P < 0.05 and 1.41 ± 1.01-fold, P < 0.05, respectively). Levels of Bax and caspase-3 protein expression in the Sham + PFT-α group did not significantly differ from these observed in the Sham + Veh group. These results suggest that inhibition of p53 activation by PFT-α ameliorates striatal apoptotic cell death in rats following TBI.

**Post-injury PFT-α treatment attenuates neuronal apoptosis in the striatum of rats with TBI.** H&E staining was performed to observe morphological abnormalities in the striatum after TBI. No significant abnormalities were observed in the sham group. In the TBI-treated group, a histological examination showed cell body shrinkage and nuclear pyknosis at 24 h after injury compared to the sham group, whereas this effect was attenuated by PFT-α treatment (Fig. 11A). This result was further confirmed by chromatin staining with DAPI. We found that nuclei of cells from the sham group were uniformly stained without condensation. However, nuclei from the TBI-treated group displayed morphological features that were typical of apoptosis, including a reduced nuclear size, high condensation, nuclear fragmentation, and some scattered apoptotic bodies.

1.00 ± 0.01-fold, P < 0.05 (Fig. 8C). Post-injury PFT-α treatment maintained the p62 protein level versus the TBI + Veh group (0.91 ± 0.11-fold, P < 0.001, respectively; Fig. 8C). Levels of Beclin-1, LC3II and p62 expressions in the Sham + PFT-α group did not significantly differ from those observed in the Sham + Veh group. These results indicated that inhibition of p53 signaling by PFT-α is involved in TBI-induced autophagy formation in rats.

**Post-injury PFT-α treatment reduces TBI-induced neurodegeneration.** Significant levels of apoptosis occur in the injured striatum after TBI. As illustrated in Fig. 9Ab, numerous FJC-positive cells were observed in the striatum at 24 h post-injury. A quantitative summary of FJC-positive cells observed in the Sham + Veh, TBI + Veh, and TBI + PFT-α groups is provided in Fig. 9B. Numbers of degenerating neurons were significantly elevated in the TBI + Veh group (177.9 ± 14.29/mm², P < 0.01) compared to the sham group (12.167 ± 3.07/mm²). In comparison, the PFT-α-treated TBI group had a significantly lower number of degenerating neurons (82.73 ± 3.07/mm², P < 0.05) compared to the TBI + Veh group.

**Post-injury PFT-α treatment attenuates expression of apoptotic-related genes and proteins in the striatum of rats with TBI.** To investigate the effect of PFT-α on TBI-induced apoptosis, expression levels of Bax and caspase-3 mRNAs and proteins were respectively examined by an RT-PCR and Western blotting. Levels of Bax and caspase-3 mRNAs in the Sham + PFT-α group did not significantly differ from those observed in the Sham + Veh group (Fig. 10A). Results showed that Bax and caspase-3 mRNA levels were significantly elevated in the TBI-treated group (1.49 ± 0.17-fold, P < 0.05 and 1.47 ± 0.21-fold, P < 0.01, respectively) compared to the sham-treated group (1. ± 0.11-fold and 1 ± 0.09-fold, respectively), whereas these effects were attenuated in the PFT-α-treated group (0.64 ± 0.05-fold, P < 0.001 and 0.61 ± 0.18, P < 0.05, respectively) (Fig. 10A). Levels of Bax and cleaved-caspase-3 proteins had significantly increased in the TBI-treated group (1.87 ± 0.15-fold, P < 0.05 and 4.68 ± 1.26-fold, P < 0.05, respectively; Fig. 10B), however both Bax and cleaved-caspase-3 expression were significantly reduced in the PFT-α treatment group (0.86 ± 0.29-fold, P < 0.05 and 1.41 ± 1.01-fold, P < 0.05, respectively). Levels of Bax and caspase-3 protein expression in the Sham + PFT-α group did not significantly differ from these observed in the Sham + Veh group. These results suggest that inhibition of p53 activation by PFT-α ameliorates striatal apoptotic cell death in rats following TBI.

**Post-injury PFT-α treatment attenuates neuronal apoptosis in the striatum of rats with TBI.** H&E staining was performed to observe morphological abnormalities in the striatum after TBI. No significant abnormalities were observed in the sham group. In the TBI-treated group, a histological examination showed cell body shrinkage and nuclear pyknosis at 24 h after injury compared to the sham group, whereas this effect was attenuated by PFT-α treatment (Fig. 11A). This result was further confirmed by chromatin staining with DAPI. We found that nuclei of cells from the sham group were uniformly stained without condensation. However, nuclei from the TBI-treated group displayed morphological features that were typical of apoptosis, including a reduced nuclear size, high condensation, nuclear fragmentation, and some scattered apoptotic bodies.
Post-injury treatment with PFT-α significantly ameliorated these nuclear abnormalities (Fig. 11B). A quantitative analysis revealed that numbers of apoptotic cells had significantly increased at 24 h in the TBI-treated group after injury (277.7 ± 11.1 cells/mm²; P < 0.001) compared to the sham group (41.5 ± 6.5 cells/mm²). PFT-α administration reduced the number of apoptotic cells (182 ± 26.5 cells/mm²; P < 0.01) compared to the TBI-treated group (Fig. 11C). We further confirmed the effect of PFT-α on neuronal apoptotic cell death in striatal tissues at 24 h after a TBI using double immunofluorescence staining. Double immunofluorescence staining using an antibody against cleaved caspase-3 combined with a NeuN antibody showed that neurons positive for cleaved caspase-3 expression in the sham group were negligible compared to those observed in the TBI-treated group (Fig. 11Da–h, respectively). Post-injury treatment with PFT-α at 5 h reduced the number of cleaved caspase3-positive neurons (Fig. 11Di–l). These findings underscore that striatal damage plays a critical role in the pathological process of TBIs.

**Discussion**

Although animal studies demonstrated that TBIs cause cortical and hippocampal neuronal loss, only a few studies have focused on striatal damage caused by TBI. The striatum is one of the major inputs into the basal ganglia. Striatal neurons can receive glutamate inputs from the cortex and dopamine (DA) innervation from the midbrain. Striatal dysfunction is associated with deficits in learning, memory, and executive function following TBI. Multiple lines of evidence imply that DA-targeted therapies represent an important clinical option for treating persistent cognitive dysfunction after TBI. Those results underscore that the striatum plays an important role in neurological function. The present work was performed in an effort to determine the effects of PFT-α, a p53 inhibitor, on TBI-induced striatal damage. We report a possible molecular mechanism of PFT-α against TBI damage in the striatum through amelioration of neurological functional deficits, attenuating neuroinflammation, oxidative stress, autophagy, and apoptosis following TBI.

The transcriptional factor, p53, plays various distinct roles in response to cell stresses, whereas inappropriate p53 activation is involved in stress-induced apoptotic signaling pathways in neurological diseases and brain injuries. Animal studies demonstrated that levels of p53 mRNA and protein were increased in the cortex and hippocampus after TBI. Our previous study demonstrated that post-injury PFT-α administration reduced p53 mRNA and p53-positive neurons in the cortex and hippocampus. Recent studies mainly focused on the role of p53 in neurons, and it is known that inhibition of p53 significantly reduced neuronal cell death.
However, it was reported that p53 is also inducible in astrocytes and microglia under pathological conditions. For example, 1 or 3 days following ischemic injury, p53 was not obviously detectable in reactive astrocytes in the forebrain. However, p53 expression in reactive astrocytes was clearly detectable in affected cortical regions (e.g., the forelimb area, hindlimb area, and parietal cortex) at 7 days following ischemic injury. It was also demonstrated that p53 was detectable in neurons, activated microglia, and astrocytes at 24 h after hypoxia-ischemia (HI) injury on postnatal day 7 in rat pups. Expressions of microglia marker proteins are dependant on specific differentiation states in CNS diseases or disease models, indicating that microglia are capable of heterogeneous functional differentiation responses to disease-relevant stimuli. It was reported that p53 mainly influences M1-like microglial behavior, supporting the adoption of a proinflammatory phenotype, but p53 activation is excluded from the population of microglia labeled by CD163, a marker of macrophages that have adopted anti-inflammatory or tissue repair phenotypes (M2-like microglia). In the present study, we observed that p53 mRNA significantly increased in the striatum, whereas p53 expression was predominantly distributed in neurons but not in microglia or astrocytes in the striatum at 24 h after the TBI. The absence of p53 expression in astrocytes and microglia is likely because the expression of p53 in activated microglia and astrocytes possibly depends upon the specific disease model employed, the timing of glial activation, the microglial phenotype, and specific brain regions examined. Moreover, we found that post-injury treatment with PFT-α reduced p53 expression and improved sensory-motor function (as revealed by a tactile adhesive removal test) and neurological deficit severity (as revealed by the mNSS test), indicating that p53 may participate in striatal pathophysiological processes of TBIs. Since there was no difference between Sham + Veh group and Sham + PFT-α group, the slight difference between TBI + PFT-α group and Sham + Veh may be due to a multiple effect of PFT-α on TBI-induced p53.

**Figure 7.** Post-injury administration of pifithrin (PFT)-α at 5 h after a traumatic brain injury (TBI) reduced 4-hydroxynonenal (HNE)-positive neurons in striatal tissues at 24 h. (A) Double immunofluorescence staining of NeuN and 4-HNE in striatal brain tissues. NeuN is shown in red, and 4-HNE is shown in green. Yellow labeling indicates colocalization. Scale bar = 50 μm. (B) Quantitative comparison of NeuN-4-HNE-positive cells in the Sham + Veh, TBI + Veh, and TBI + PFT-α groups. Data are presented as the mean ± SEM (n = 3 per group). *P < 0.05 and **P < 0.01 vs. Sham + Veh group; P < 0.05 vs. TBI + Veh group. (C) Micrographs show immunofluorescence staining using anti-GFAP (green in a), anti-ED1 (green in d), or anti-4-HNE (red in b and e). Merged images show that there is no colocalization of GFAP and 4-HNE (c), or ED1 and 4-HNE after TBI.
mRNA transcription including direct effect and indirect effect on other TBI-activated pathways that influence p53 transcription. Our speculation may need further investigation.

The underlying mechanisms of TBIs are complicated. Neuroinflammation is one of the crucial factors among the pathophysiological manifestations of TBIs. The presence of a number of markers of neuroinflammation is evident in insult regions, such as elevated production of proinflammatory cytokines and ROS by activated glial cells. Emerging evidence suggests that p53 is primarily involved in cancer biology and also participates in various novel functions in the brain, such as modulation of glial function and mediation of the pathophysiological process of neurodegenerative disease. For example, induction of microglial p53 expression by neurotoxic activators (e.g., amyloid beta peptide and lipopolysaccharide) caused cerebellar granule neuronal toxicity, whereas inhibition of p53 by PFT-α reduced neurotoxicity via modulation of induced nitric oxide synthase expression and TNF-α secretion. p53 and NF-κB were shown to engage in functional cross-talk and participate in modulation of inflammatory responses, indicating that p53 plays a critical role in innate immune function. In this study, we found that striatal astrocytes displayed a hypertrophic size and microglia displayed an ameboid morphology (both characteristics of activated glia) which were accompanied by TNF-α, IL-1β, and IL-6.

Figure 8. Post-injury administration of pifithrin (PFT)-α at 5 h after a traumatic brain injury (TBI) reduced levels of Beclin-1, light chain (LC)3-II and p62 expression in striatal tissues at 24 h. Levels of Beclin-1 (A), LC3 (B) and p62 (C) expression in striatal tissues from the Sham + Veh, Sham + PFT-α, TBI + Veh, and TBI + PFT-α groups were analyzed by Western blotting. Levels of Beclin-1, LC3I, LC3II and p62 expression were normalized to β-actin and then quantified. Data are expressed as the mean ± SD (n = 4 per group). *P < 0.05 and **P < 0.001 vs. Sham + Veh group; †P < 0.05 and ‡P < 0.01 vs. TBI + Veh group.

Figure 9. Post-injury administration of pifithrin (PFT)-α at 5 h after a traumatic brain injury (TBI) decreased Fluoro Jade C (FJC)-positive cells in striatal tissues at 24 h. (A) Photomicrographs of FJC-stained regions of interest in the Sham + Veh, TBI + Veh, and TBI + PFT-α groups at 24 h. The total number of FJC-positive cells is expressed as the mean number per field of view. Data are expressed as the mean ± SD (n = 4 per group). *P < 0.05 and **P < 0.01 vs. Sham + Veh group; †P < 0.05 vs. TBI + Veh group.
cytokine mRNA expression and protein production after TBI. However, morphological features of activated glia
and expression of cytokines were attenuated by PFT-α, indicating that TBI-induced glial activation and neuroin-
flammation are possibly controlled, at least in part, via p53; however, the exact cellular and molecular mecha-
nisms remain to evaluated in the future.

It is now generally accepted that neuronal cell death due to oxidative stress is a common characteristic of
TBI.66–68 The degree of oxidative stress in different brain regions (e.g., the cortex, hippocampus, and striatum)
is dependent on the TBI intensity.66 In line with our observations, there are a number of studies showing that
treatment with antioxidant N-acetyl cysteine (NAC) or glutathione reduced the damage produced by a TBI in
preclinical models.69,70 The p53 tumor suppressor protein was proposed as a key mediator of stress responses
because it plays an essential role in neuronal cell death.66–68 It was demonstrated that p53 induces cell death by
multiple molecular pathways involving regulation of antioxidant, pro-oxidant, proapoptotic, and autophagic gene
expression.71 The brain is highly sensitive to lipid peroxidation (LP) due to its high contents of polyunsaturated
fatty acids and high levels of iron.72 The most notable end products of LP, 4-hydroxynonenal (4-HNE), can bind
to proteins, modifying their structures and functions, which in turn causes neuronal damage.66,73 Consistent with
that study, levels of malondialdehyde (MDA), the end product of LP, increased after TBI; however, treatment with
the D2 receptor agonist, bromocriptine, attenuated levels of MDA production and improved histological and
cognitive outcomes.74 Those results indicate that oxidative stress plays an important role in TBI. Since HO-1, which
is associated with the endogenous defense response, represents an important cellular cytoprotective mechanism
against oxidative damage by degrading toxic heme into free iron, carbon monoxide, and biliverdin.75,76 It was pro-
posed that brain redox homeostasis (e.g., HO-1) can be regulated by the interplay between superoxide dismutase
2 and p53.77 In the present study, we found that HO-1 expression was upregulated after a TBI, whereas post-injury
treatment with the p53 inhibitor, PFT-α, enhanced the upregulation of HO-1 mRNA and protein increases, com-
pared to the TBI group. Since HO-1 mediates cellular responses to oxidative stress, we further examined the effect
of PFT-α on oxidative stress induced by the TBI. We found that the number of 4-HNE-positive cells significantly

Figure 10. Post-injury administration of pifithrin (PFT)-α at 5 h after a traumatic brain injury (TBI) reduced
both transcriptional and translational expression levels of Bax and cleaved caspase-3 in striatal tissues at 24 h.
(A) Levels of Bax and caspase-3 mRNA expression in striatal tissues from the Sham + Veh, Sham + PFT-α,
TBI + Veh, and TBI + PFT-α groups were analyzed by an RT-PCR. (B) Levels of Bax and cleaved caspase-3
protein expression in striatal tissues from each group were analyzed by Western blotting. Levels of mRNA and
protein expression were normalized to β-actin and then quantified. Multiples of change are relative to that of
the sham group. Data are expressed as the mean ± SD (n = 3 per group). *P < 0.05 and **P < 0.01 vs. Sham + Veh
group; †P < 0.05 and ‡P < 0.01 vs. TBI + Veh group.
increased in the rat striatum after the TBI, whereas this effect was reduced by PFT-α. Our results showed that TBI-induced lipid oxidation mainly occurs in neurons but not in astrocytes or microglia. The possible explanation for this observation is that neurons, which contain lower levels of glutathione compared to glia, are more vulnerable to oxidative damage. In addition, the presence of a number of markers of neuroinflammation is evident in injured regions, such as elevated production of proinflammatory cytokines, and ROS by activated glial cells. Sustained production of these factors contributes to neuronal oxidative damage. However, whether glial cell activation in the brain is beneficial or harmful remains unclear. Most likely glial activation may be both beneficial and harmful, depending upon the degree and longevity of the activity. Hence, expressions and releases of neurotrophic or harmful substances in response to neuronal injuries are likely determinants of neuronal viability. Our findings suggest that PFT-α attenuates TBI-induced oxidative stress possibly via inducing HO-1 expression and attenuating the number of 4-HNE-positive cells. Collectively, these results highlight the important role of p53 in countering TBI-induced oxidative stress. However, questions remain as to how PFT-α can reduce oxidative damage after TBI.

Since HO-1 also mediates cellular responses to autophagy, we also examined the role of p53 in TBI-induced autophagy. Emerging evidence reported that oxidative stress is essential for induction of autophagy. Increased autophagy was demonstrated to be involved in animal models of TBI. Basal expression of autophagy is a homeostatic process of recycling dysfunctional macromolecules and organelles in physiological conditions. However,
under certain pathological circumstances (e.g., oxidative stress), autophagy increases and is perhaps involved in cytoprotection or cell death. Beclin-1, a marker of autophagic activation, is a key protein involved in regulating autophagy. LC3-II is another autophagic marker. Conversion of LC3-I to LC3-II via the addition of phosphatidylethanolamine is essential for the formation of autophagosomes, and expression of the LC3-II protein can reflect autophagic activity. The sequestosome 1 (SQSTM1)/A170 protein, also known as the p62 protein, was suggested to be correlated with ubiquitinated proteins and directly binds to LC3, which may regulate the selective autophagic clearance of the p62 substrate. In the present study, we found that post-injury PFT-α treatment significantly decreased TBI-induced elevation of Beclin and LC3-II, and maintained p62 levels in the striatum, suggesting a decreased ability of autophagy to degrade p62. A possible mechanism may be supported by this study which showed that p53 can inhibit mTOR, a suppressor of autophagy, indicating that p53 has an important role in autophagy regulation after TBI. In accordance with these biochemical changes, our histologic evaluation revealed that PFT-α also significantly reduced FJC-positive cells (a marker of degenerating neurons) and conferred neuroprotection. It is known that oxidative stress-induced DNA damage can overwhelm repair systems, and activation of p53 cascades may initiate p53-mediated apoptosis. Proapoptotic-related proteins, such as Bax and caspase-3, can be induced by TBI. Upregulation of p53 and a decrease in the ratio of Bcl-2 (an antiapoptotic protein) to Bax (a proapoptotic protein) accompanied neuronal apoptosis in a closed-head injury rat model. In this study, PFT-α administration post-injury reduced miRNA and protein levels of Bax and caspase-3 in striatal tissues after TBI. These results were further confirmed by fewer apoptotic nuclei in PFT-α-treated than vehicle-treated TBI animals using DAPI staining. Taken together, pharmacological inhibition of p53 by PFT-α attenuated TBI-induced autophagy and neuronal apoptotic cell death, underscoring the importance of p53 activation in the pathophysiology of TBIs.

Whereas most published articles on PFT-α are consistent with its p53 inhibitory activity, it is known that PFT-α analogs also possess some p53-independent effects. It was shown that PFT-α is a potent agonist of the aryl hydrocarbon receptor (AhR), and that this activity of PFT-α analogs is not related to its p53-inhibitory properties. In addition, PFT-α can directly inhibit the catalytic activities of recombinant isoforms of the human cytochrome P450 superfamily of enzymes, CYP1A1, CYP1A2, and CYP1B1. Although this has yet to be evaluated in vivo, this observation provides a plausible explanation for the protective actions of PFT-α against chemical carcinogens. Finally, in at least some cell systems, PFT-α is capable of suppressing the heat shock response and inhibiting glucocorticoid receptor signaling. These examples show that the actions of PFT-α depend to some degree on the cell type evaluated, particularly whether of neuronal or non-neuronal origin. It is also likely such distal effect of injury is dependent on injury intensity so that it would be important to assess the time course of striatal p53 upregulation, immune response, neurodegeneration, oxidative stress, autophagy apoptosis, activation of glial cells and neuroinflammation after TBI for the delineation of primary and secondary injury and injury progression. However, these events are all maximized at specific time points after the TBI. We chose to measure these parameters at their maximum values based on our previous studies to demonstrate the efficacy of PFT-α.

In conclusion, results of the present study suggest that mechanisms underlying the neuroprotective effects of PFT-α may act in part through amelioration of neurological functional deficits, attenuating neuroinflammation, oxidative stress, autophagy, and apoptosis in the striatum following an experimental TBI in rats. Although such striatal changes could be indirect effect due to less damages in cortex or hippocampus but not due to direct regulation of immune response, astrocytes activation, HO-1 upregulation following our TBI protocol, such a possibility will require further investigation. In any event, inhibition of p53-mediated pathophysiological processes by PFT-α can possibly be developed into a novel therapeutic strategy for TBIs. Hence, further evaluation and optimization of PFT-α for potential applications in clinical TBIs are required.

Methods

Animal model of TBI using a controlled cortical impactor (CCI). All animals were treated in accordance with international guidelines for animal research, and the study design was approved by the animal ethics committee of Taipei Medical University. Animals were housed in groups in a temperature- (21~25 °C) and humidity (45~50%) controlled room with a 12-h light/dark cycle and ad libitum access to pellet chow and water. A CCI was used to produce TBI in rats as previously described. Male Sprague-Dawley rats (250~300 g in body weight) were randomized into four groups. Sham animals received anesthesia and a craniotomy but no TBI, then received either a Veh (10% DMSO in saline, iv.) or a PFT-α (a p53 inhibitor) injection (2 mg/kg, iv.) at 5 h after the craniotomy, and were respectively designated the Sham + Veh or Sham + PFT-α group. Another two groups of animals were anesthetized and placed in a stereotaxic frame and subjected to a TBI. Injury was made using a CCI instrument with a rounded metal tip (5 mm in diameter) as we previously described. Briefly, a craniotomy was performed over the left parietal cortex, centered on the coronal suture and 3.5 mm lateral to the sagittal suture. A velocity of 4 m/s and a deformation depth of 2 mm below the dura were used. TBI animals also received either the Veh or PFT-α at 5 h post-injury and were designated the TBI + Veh or TBI + PFT-α group, respectively. The body temperature was monitored throughout the surgery with a rectal probe; it was maintained at 37 °C using a heating pad. Rats were placed in a heated cage to maintain their body temperature while recovering from anesthesia. No temperature changes were seen after PFT-α administration in normal or sham animals. Behavioral and histological analyses were carried out by an experimenter blinded to the treatment conditions. All animals were sacrificed at 24 h after the craniotomy. Figure 1 depicts the grouping of sham and TBI animals receiving Veh or PFT-α for morphological evaluations or biochemical measurements of messenger (m)RNA and protein levels. The "striatal region" we isolated and dissected for biochemical measurements included both the dorsal and ventral striatum. However, all the immunostaining images were taken from the dorsal striatum. For morphological studies, the brain of each animal was sectioned (10 μm). Sections were selected for HE, FJC, DAPI, and immunofluorescence staining using standard methods. Our selected treatment time of 5 h and dosage were based on our prior study indicating that the secondary phase of neuronal injury following TBI can be attenuated if appropriate treatment is initiated within this time window.

www.nature.com/scientificreports/
Two small adhesive-backed stickers (each 113.1 mm²) were used as bilateral tactile stimuli that were placed on the swing to either on the left or right side. (3) A tactile removal test was used to evaluate somatosensory function. Right-biased swings/the total number of swings) were then quantified. (2) Body asymmetry was quantitatively analyzed with the use of the EBST. As the TBI was performed on the left side, resulting weakness (hemiparesis) developed on the right side. The frequency of left/right swings was scored across 20 consecutive trials and expressed as a percentage [calculated by: (number of swings performed on the left side, resulting weakness (hemiparesis) developed on the right side. The frequency of left/right swings was scored across 20 consecutive trials and expressed as a percentage [calculated by: (number of right-biased swings/the total number of swings) × 100%]. An uninjured animal showed an equal frequency to swing to either on the left or right side. (3) A tactile removal test was used to evaluate somatosensory function. Two small adhesive-backed stickers (each 113.1 mm²) were used as bilateral tactile stimuli that were placed on the distal-radial region of the wrist of each forelimb. Rats were pre-trained daily for 3 days before the TBI. The time required for the rat to remove the sticker from the forelimb was recorded in five trials at 24 h after the TBI. (4) To compare the neurological deficit severity in TBI rats, an mNSS which is a composite of motor, sensory, reflex, and balance tests was performed. One point was scored for the inability to perform the test or for the lack of a tested reflex; thus, the higher the score, the more severe the injury. Neurological function was graded on a scale of 0–18 (normal score, 0; maximal deficit score, 18).

**Behavioral evaluation of neurological outcomes.** Behavioral testing was performed before the TBI and at 24 h after the TBI. The evaluation consisted of a beam walk test, an elevated body swing test (EBST), a tactile adhesive removal test, and a modified neurological severity score (mNSS) assessment. All were performed by an observer blinded to the experimental groups. These procedures were performed as previously described, with some modifications. Briefly, (1) the beam walk test was used to assess the fine motor coordination and balance. Five trials were recorded 1 h before the TBI (baseline) and at 24 h after the TBI. Mean values of the latency were then quantified. (2) Body asymmetry was quantitatively analyzed with the use of the EBST. As the TBI was performed on the left side, resulting weakness (hemiparesis) developed on the right side. The frequency of left/right swings was scored across 20 consecutive trials and expressed as a percentage [calculated by: (number of right-biased swings/the total number of swings) × 100%]. An uninjured animal showed an equal frequency to swing to either on the left or right side. (3) A tactile removal test was used to evaluate somatosensory function. Two small adhesive-backed stickers (each 113.1 mm²) were used as bilateral tactile stimuli that were placed on the distal-radial region of the wrist of each forelimb. Rats were pre-trained daily for 3 days before the TBI. The time required for the rat to remove the sticker from the forelimb was recorded in five trials at 24 h after the TBI. (4) To compare the neurological deficit severity in TBI rats, an mNSS which is a composite of motor, sensory, reflex, and balance tests was performed. One point was scored for the inability to perform the test or for the lack of a tested reflex; thus, the higher the score, the more severe the injury. Neurological function was graded on a scale of 0–18 (normal score, 0; maximal deficit score, 18).

**Measurement of cytokines.** Concentrations of cytokines (TNF-α, IL-1β, and IL-6) were measurement by enzyme-linked immunosorbent assay (ELISA) kits (BioSource International, Camarillo, CA, USA) according to the manufacturer’s protocol.

**Western blot analysis.** Under deep anesthesia (sodium pentobarbital i.p.; 50 mg/kg), rats were euthanized at 24 h. The striatal region of the brain was rapidly isolated and homogenized, and total proteins were extracted using protein extraction buffer (Mammalian Cell-PE LBTM, Geno Technology, USA) containing protease and phosphatase inhibitors (Complete Mini, Roche Diagnostics, Indianapolis, IN, USA). Lysed tissues were centrifuged at 12,500 rpm for 15 min (at 4 °C), and the supernatant was collected for storage at −80 °C or to perform a Western blot analysis. Proteins were separated by gel electrophoresis, and then electroblotted onto polyvinylidene difluoride (PVDF) membranes (PerkinElmer Life Sciences, USA). Membranes were blocked with 5% non-fat milk, and then incubated overnight at 4 °C with the indicated antibodies, including heme oxygenase (HO)-1, Bax, cleaved caspase-3, Beclin-1, LC3-I/II, and p62 (1:100 dilution) followed by an appropriate secondary antibody (1:2 × 10⁴ dilution) for 1 h at room temperature. Signals were visualized using enhanced chemiluminescent (ECL) detection reagents (PerkinElmer Life Sciences). The membrane was then stripped and reprobed with an antibody specific for β-actin (1:10⁴ dilution) to ensure the accuracy of each loading. Protein expression was quantified by a BioImaging System (Level Biotechnology).

**Real-time reverse-transcription polymerase chain reaction (RT-PCR) assay.** Total RNA was extracted from striatal tissues using the TRIzol® reagent (Invitrogen Life Technologies, Paisley, Scotland). Total RNA (3 µg) was reverse-transcribed into complimentary (c)DNA using the Rever Tra Ace-α First-strand cDNA Synthesis Kit (Toyobo Life Science, Japan). The resulting cDNA was incubated with a Rotor-Gene SYBR Green kit (Applied Biosystems, Foster City, CA, USA) and primers. Primers sequence used in the RT-PCR are shown in Table 1. For the semiquantitative analysis, we performed 40 amplification cycles (denaturation at 95 °C for 5 s and annealing at 60 °C for 10 s) and p62 (1:10⁴ dilution) followed by an appropriate secondary antibody (1:2 × 10⁴ dilution) for 1 h at room temperature. Signals were visualized using enhanced chemiluminescent (ECL) detection reagents (PerkinElmer Life Sciences). The membrane was then stripped and reprobed with an antibody specific for β-actin (1:10⁴ dilution) to ensure the accuracy of each loading. Protein expression was quantified by a BioImaging System (Level Biotechnology).

**Table 1. Primer sequences.**

| Gene of interest | Forward Primer (5’-3’) | Reverse Primer (5’-3’) |
|-----------------|------------------------|-----------------------|
| TNF-α           | CTCCTCTCA TCCCCGCTGTTG | GAAACTCTCTCCTGTGTTGGG |
| IL-1β           | GTTGAGTCTGACAGTTCCG  | CAACATGTCGCCACCATGTC |
| IL-6            | TTCTGGGAGCTGTGTGGAC   | AATTAAGCCGCCAGTTGGAGA |
| HO-1            | GAGATAGAGCGAAACAGCAGA | GTCCTGTACCCGAAACGATA |
| il5            | CCATGGGCCATCTACAGAGA   | TGGTGTCGACATCTGAGCATA |
| Bax             | GTGAGCGGCTGCTTGTCT    | GTGGGGGTCCGGAGAAGTAG  |
| Caspase 3       | AATCTAAAGGAGGCGCTAGT  | GCTTGTTGGGCTACAGTTTC |
| β-actin         | GACCCCAGATCATGTTGACCTTC | GTGGACCGTAACACTCCGTAG |

**Fluoro jade C (FJC) staining.** FJC, a derivative of polyaniionic fluorescein, selectively binds to degenerating neurons. We used an FJC ready-to-dilute staining kit (TR-100-F, Biosensis) to identify degenerating neuronal cells according to the manufacturer’s protocol with some modifications. Brain sections from the different treatment groups were deparaffinized, rehydrated, and incubated in distilled water for 2 min. Brain sections were incubated in a solution of potassium permanganate (1:15) for 10 min, rinsed in distilled water for 2 min, and then incubated in the FJC solution (1:25) for 30 min. After incubation, brain slides were washed and mounted.
on coverslips with Vecta-shield mounting medium (Vector Laboratories, Burlingame, CA, USA). All sections were observed and photographed using a fluorescent inverted microscope (IX70, Olympus, Japan). Numbers of FJC-positive cells were counted in three randomly selected fields per slide by means of SPOT image analysis software (Diagnostic Instruments). Numbers of FJC-positive cells observed on the slides from different treatment groups were counted and used to generate a mean number per treatment group.

**Double immunofluorescence staining.** Coronal sections (10 μm) were obtained from the anterior area of the left hemisphere. All sections were dried, rehydrated in phosphate-buffered saline (PBS), and rinsed in PBS. Sections were blocked for 60 min in 5% bovine serum albumin (BSA) (PBS containing 5% BSA and 0.2% Triton X-100, Sigma, St. Louis, MO, USA) and incubated with the appropriate primary antibodies, either an anti-NeuN antibody (a neuronal marker; mouse monoclonal anti-NeuN from Millipore, USA; rabbit polyclonal anti-NeuN from Cell Signaling, USA; 1:500), anti-GFAP antibody (an astrocyte marker; mouse monoclonal anti-GFAP from Abcam, USA; rabbit polyclonal anti-GFAP from Cell Signaling, USA; 1:1000), mouse anti-ED1 (a microglial marker, Serotec), rabbit anti-Iba1 (a microglial marker, GeneTex), mouse anti-p53 antibody (Abcam, USA; 1:300), rabbit anti-4-HNE antibody (Abcam; 1:300), or rabbit anti-cleaved caspase-3 (Cell Signaling, USA; 1:300) at 4 °C overnight and with a secondary antibody (Alexa Fluor® 488 goat anti-rabbit/anti-mouse immunoglobulin G (IgG) or Alexa Fluor® 594 goat anti-rabbit/anti-mouse IgG; Jackson ImmunoResearch, West Grove, PA, USA; 1:250) for 1 h at room temperature. Sections were mounted with mounting medium H-1000 (Vector Laboratories). Immunofluorescence images were viewed using an inverted Olympus IX 70 microscope equipped with a cooled CCD camera and SPOT advanced software (Diagnostic Instruments, Sterling Heights, MI, USA). Images of NeuN-p53-positive cells or NeuN-4-HNE-positive cells in the sham, TBI + Veh, and TBI + PFT-α groups (in three randomly selected fields within the calibrated area) were captured in a personal computer as digital micrographs and counted.

**Hematoxylin and eosin (H&E) staining.** Histological and morphological abnormalities in the striatum of the sham, TBI + Veh, and TBI + PFT-α groups were examined with an H&E staining kit (GeneCopeia™; USA) according to the manufacturer’s protocol.

**Morphological analysis of apoptotic nuclei.** To visualize apoptotic nuclei, sections were fixed in 4% paraformaldehyde (PFA) and stained with the fluorescent DNA-binding dye, 4,6-diamidino-2-phenylindole (DAPI) (5 μg/ml, Sigma-Aldrich, St. Louis, MO, USA) for 1 min. After incubation, brain slides were washed and mounted on coverslips with Vecta-shield mounting medium (Vector Laboratories). Images of apoptotic cells in the sham, TBI + Veh, and TBI + PFT-α groups (in three randomly selected fields within the calibrated area) were captured in a personal computer as digital micrographs and counted.

**Statistical analysis.** All data are presented as the mean ± standard error of the mean (SEM). Statistical significance was assessed by a one-way analysis of variance (ANOVA) followed by Newman-Keuls’ test using the SigmaStat program (Jandel Scientific, San Rafael, CA, USA). Significance was set at P < 0.05.

**References**

1. Das, M., Mohapatra, S. & Mohapatra, S. S. New perspectives on central and peripheral immune responses to acute traumatic brain injury. *Journal of Neuroinflammation* **9**, 236 (2012).
2. Sauerbeck, A., Hunter, R., Bing, G. & Sullivan, P. G. Traumatic brain injury and trichloroethylene exposure interact and produce functional, and mitochondrial deficits. *Experimental Neurology* **234**, 85–94 (2012).
3. Shin, S. S., Bray, E. R. & Dixon, C. E. Effects of nicotine administration on striatal dopamine signaling after traumatic brain injury in rats. *Journal of Neurotrauma* **29**, 843–850 (2012).
4. Wagner, A. K. et al. The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI. *Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism* **34**, 1328–1339 (2014).
5. Shin, S. S., Bray, E. R., Zhang, C. Q. & Dixon, C. E. Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats. *Brain Research* **1369**, 208–215 (2011).
6. Harmon, J., Gibbs, W., Whittaker, R., Schnellmann, R. & Adkins, D. L. Striatal Mitochondrial Disruption Following Severe Traumatic Brain Injury. *Journal of Neurotrauma* **34**, 487–494 (2017).
7. Maas, A. L., Stocchetti, N. & Bullock, R. Moderate and severe traumatic brain injury in adults. *The Lancet. Neurology* **7**, 728–741 (2008).
8. Zhang, Y. B. et al. Autophagy is activated and might protect neurons from degeneration after traumatic brain injury. *Neurosci Bull* **24**, 143–149 (2008).
9. Bains, M. & Hall, E. D. Antioxidant therapies in traumatic brain and spinal cord injury. *Biochimica et Biophysica acta* **1822**, 675–684 (2012).
10. Cheng, G., Kong, R. H., Zhang, L. M. & Zhang, J. N. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotent therapeutic strategies. *British Journal of Pharmacology* **167**, 699–719 (2012).
11. Morrison, R. S., Kinoshita, Y., Johnson, M. D., Guo, W. & Garden, G. A. p53-dependent cell death signaling in neurons. *Neurochemical Research* **28**, 15–27 (2003).
12. Marine, J. C. et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. *Cell Death and Differentiation* **13**, 927–934 (2006).
13. Xu, F. L. et al. Expression of p53 in neonatal mice following hypoxia-ischemia and effects of its inhibitor on neonatal brain injury. *Zhongguo Dang Dai Er Ke Za Zhi* **8**, 137–140 (2006).
14. Nijboer, C. H. et al. Targeting the p53 pathway to protect the neonatal ischemic brain. *Ann Neurol* **70** (2011).
15. Rachmany, L. et al. Cognitive impairments accompanying rodent mild traumatic brain injury involve p53-dependent neuronal cell death and are ameliorated by the tetrahydrobenzothiazole PFT-alpha. *PLoS One* **8**, e79837 (2013).
16. Wan, C. et al. Involvement of upregulated p53-induced death domain protein (PIDD) in neuronal apoptosis after rat traumatic brain injury. *Journal of Molecular Neuroscience: MN* **31**, 695–702 (2013).
17. Ding, K. et al. Rapamycin protects against apoptotic neuronal death and improves neurologic function after traumatic brain injury in mice via modulation of the mTOR-p53-Bax axis. *The Journal of Surgical Research* **194** (2015).
18. Hong, M. Y. et al. Effect of c-Jun NH(2)-terminal kinase-mediated p53 expression on neuron autophagy following traumatic brain injury in rats. *Chinese Medical Journal* **125**, 2019–2024 (2012).
19. Long, J. et al. INK3 involvement in nerve cell apoptosis and neurofunctional recovery after traumatic brain injury. *Neural Regeneration Research* **8**, 1491–1499 (2013).
20. Feng, Z., Zhang, H., Levine, A. J. & Jin, S. The coordinate regulation of the p53 and mTOR pathways in cells. *Proceedings of the National Academy of Sciences of the United States of America* **102**, 8204–8209 (2005).
21. Gao, Z. et al. DRAM Is Involved in Regulating Nucleoside Analog-Induced Neuronal Autophagy in a p53-Independent Manner. *Molecular Neurobiology* (2017).
22. Scherz-Shouval, R. et al. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. *The EMBO Journal* **26** (2007).
23. Kourtis, N. & Tavernarakis, N. Autophagy and cell death in model organisms. *Cell Death and Differentiation* **16**, 21–30 (2009).
24. Shintani, T. & Klionsky, D. J. Autophagy in health and disease: a double-edged sword. *Science* **306**, 990–995 (2004).
25. Mizushima, N., Levine, B., Cuervo, A. M. & Klionsky, D. J. Autophagy fights disease through cellular self-digestion. *Nature* **451** (2008).
26. Zeng, X., Overmeyer, J. H. & Maltese, W. A. Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosis and lysosomal enzyme trafficking. *Journal of Cell Science* **119**, 259–270 (2006).
27. Maitri, M. C. et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. *The EMBO Journal* **26** (2007).
28. Liang, X. H. et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. *Journal of Virology* **72**, 8586–8596 (1998).
29. Nopparat, C., Porter, J. E., Ebadi, M. & Govitrapong, P. The mechanism for the neuroprotective effect of melatonin against neuronal loss and improves cognitive deficits after experimental traumatic brain injury. *Neurobiology of Disease* **17**, 363–375 (2004).
30. Pietrancosta, N. et al. Imino-tetrahydro-benzothiazole derivatives as p53 inhibitors: discovery of a highly potent in vivo inhibitor and its action mechanism. *J Med Chem* **49** (2006).
31. Duan, W. et al. P53 inhibition attenuates neuronal loss, microglia activation and neurological deficits after traumatic brain injury. *Cell Death and Differentiation* **16**, 869–878 (2009).
32. Balas, J. W., Wagner, A. K., Kline, A. E. & Dixon, C. E. Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis. *Neuroscience and Biobehavioral Reviews* **33**, 981–1003 (2009).
33. Leker, R. R., Aharonowiz, M., Greig, N. H. & Ovadia, H. The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. *Experimental Neurology* **187**, 478–486 (2004).
34. Ansari, M. A., Roberts, K. N. & Schell, S. W. Oxidative stress and modification of synaptic proteins in hippocampus after traumatic brain injury. *Free Radical Biology & Medicine* **45**, 443–452 (2008).
35. Tietze, F. et al. Oxidative stress in brain according to traumatic brain injury intensity. *The Journal of Surgical Research* **164**, 316–320 (2010).
36. Rodriguez-Rodriguez, A., Egea-Guerrero, J. J., Murillo-Cabezas, F. & Carrillo-Vico, A. Oxidative stress in traumatic brain injury. *Current Medicinal Chemistry* **21**, 1201–1211 (2014).
37. Zhang, J., Moschhatalis, S., Kaur, C. & Ling, E. Changes in apoptosis-related protein (p53, Bax, Bcl-2, and Fas) expression with DNA fragmentation in the central nervous system in rats after closed head injury. *Neuroscience Letters* **290**, 89–92 (2000).
38. Jobetti, I., Hooper, C. & Pocco, J. M. Microglial p53 activation is detrimental to neuronal synapses during activation-induced inflammation: Implications for neurodegeneration. *Neuroscience Letters* **583**, 92–97 (2014).
39. Ferradini, M. L. & Devesa, I. Inducers of heme oxygenase-1. *Current Pharmaceutical Design* **14**, 473–486 (2008).
40. Sarkar, C. et al. Impaired autophagy flux is associated with neuronal cell death after traumatic brain injury. *Autophagy* **10**, 2208–2222 (2014).
41. Yao, J., Zheng, K. & Zhang, X. Rosiglitazone exerts neuroprotective effects via the suppression of neuronal autophagy and apoptosis in the cortex following traumatic brain injury. *Molecular Medicine Reports* **12**, 6591–6597 (2015).
42. Stocca, B. A. et al. PARP-1 inhibition attenuates neuronal loss, microglia activation and neurostructural deficits after traumatic brain injury. *Journal of Neurotrauma* **31**, 758–772 (2014).
43. Yang, L. Y. et al. Post-trauma administration of the pifithrin-alpha oxygen analog improves histological and functional outcomes after experimental traumatic brain injury. *Experimental Neurology* **269**, 56–66 (2015).
44. Bales, J. W. et al. The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: a novel therapeutic target in traumatic brain injury. *Experimental Neurology* **229**, 300–307 (2011).
45. Bales, J. W., Wagner, A. K., Kline, A. E. & Dixon, C. E. Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis. *Neuroscience and Biobehavioral Reviews* **33**, 981–1003 (2009).
46. Morrison, R. S. & Kinoshita, Y. The role of p53 in neuronal cell death. *Cell Death and Differentiation* **7** (2000).
47. Plesnila, N. et al. Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity. *Cell Death and Differentiation* **14**, 1529–1541 (2007).
48. Schorer, M. E. et al. Early and sustained increase in the expression of hippocampal IGF-1, but not EPO, in a developmental rodent model of traumatic brain injury. *Journal of Neurotrauma* **27**, 2011–2020 (2010).
49. Wang, D. B., Kinoshita, C., Kinoshita, Y. & Morrison, R. S. p53 and mitochondrial function in neurons. *The Journal of Surgical Research* **182**, 1186–1197 (2014).
50. Yang, L. Y. et al. Post-traumatic administration of the p53 inactivator pifithrin-alpha oxygen analogue reduces hippocampal neuronal loss and improves cognitive deficits after experimental traumatic brain injury. *Neurobiology of Disease* **96**, 216–226 (2016).
51. Jobetti, I. D., Hooper, C., Garden, G. A. & Pocco, J. M. Emerging roles of p53 in glial cell function in health and disease. *Glia* **60**, 515–529 (2012).
52. Su, W. et al. Thep53 transcription factor modulates microglia behavior through microRNA-dependent regulation of c-Maf. *J Immunol* **192**, 358–366 (2014).
53. Chung, Y. H. et al. Enhanced expression of p53 in reactive astrocytes following transient focal ischemia. *Neurological Research* **24**, 324–328 (2002).
54. Colton, C. A. Heterogeneity of microglial activation in the innate immune response in the brain. *Journal of Neuroimmune Pharmacology: the official Journal of the Society on Neuroimmune Pharmacology* **4**, 399–418 (2009).
55. Colton, C. & Wilcock, D. M. Assessing activation states in microglia. *CNS & Neurological Disorders Drug Targets* **9**, 174–191 (2010).
56. Jayadev, S. et al. Transcription factor p53 influences microglial activation phenotype. *Glia* **59** (2011).
57. Pleiss, B. et al. The Anti-Inflammatory Effects of the Small Molecule Pifithrin-micro on BV2 Microglia. *Developmental Neuroscience* **37**, 363–375 (2015).
58. Kumar, A. & Loane, D. J. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. *Brain, Behavior, and Immunity* **26** (2012).
60. Lozano, D. et al. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. *Neuropsychiatric Disease and Treatment* **11**, 97–106 (2015).

61. Kou, Z. & VandeVord, P. J. Traumatic white matter injury and giall activation: from basic science to clinics. *Glia* **62**, 1831–1855 (2014).

62. Karve, I. P., Taylor, J. M. & Crack, P. J. The contribution of astrocytes and microglia to traumatic brain injury. *British Journal of Pharmacology* (2015).

63. Davenport, C. M., Sevastou, I. G., Hooper, C. & Pocock, J. M. Inhibiting p53 pathways in microglia attenuates microglial-evoked neurotoxicity following exposure to Alzheimer peptides. *Journal of Neurochemistry* **112**, 552–563 (2010).

64. Komarova, E. A. et al. p53 is a suppressor of inflammatory response in mice. *FASEB Journal: official publication of the Federation of American Societies for Experimental Biology* **19**, 1030–1032 (2005).

65. Dijsselbloem, N. et al. A critical role for p53 in the control of NF-kappaB-dependent gene expression in TLR4-stimulated dendritic cells exposed to Genistein. *J Immunol* **178**, 5048–5057 (2007).

66. Smith, J. A., Park, S., Krause, J. S. & Banik, N. L. Oxidative stress, DNA damage, and the telomeric complex as therapeutic targets in acute neurodegeneration. *Neurochemistry International* **62**, 764–775 (2013).

67. Webster, K. M. et al. Progesterone treatment reduces neuroinflammation, oxidative stress and brain damage and improves long-term outcomes in a rat model of repeated mild traumatic brain injury. *Journal of Neuroinflammation* **12**, 238 (2015).

68. Chen, T. et al. The AMPAR Antagonist Perampanel Attenuates Traumatic Brain Injury Through Anti-Oxidative and Anti-Inflammatory Activity. *Cellular and Molecular Neurobiology* **37**, 43–52 (2017).

69. Reed, T. T. et al. Proteomic identification of nitrated brain proteins in traumatic brain-injured rats treated postinjury with gamma-glutamylcysteine ethyl ester: the role in the role of glutathione as a potential therapeutic strategy for traumatic brain injury. *Journal of Neuroscience Research* **87**, 408–417 (2009).

70. Sendt, N., Nazirzada, M. & Voruker, V. N-acetylcysteine and selenium modulate oxidative stress, antioxidant vitamin and cytokine values in traumatic brain injury-induced rats. *Neurochemical Research* **39**, 685–692 (2014).

71. Budanov, A. V. The role of tumor suppressor p53 in the antioxidant defense and metabolism. *Subcell Biochem* **85**, 337–358 (2014).

72. Hall, E. D., Vaishnav, R. A. & Mustafa, A. G. Antioxidant therapies for traumatic brain injury. *Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics* **7**, 51–61 (2010).

73. Egle, M. R. et al. Physiological role of mGSTA4-4, a glutathione S-transferase metabolizing 4-hydroxynonenal: generation and analysis of mGSTa null mice. *Toxicology and Applied Pharmacology* **194**, 296–308 (2004).

74. Kline, A. E., Massucci, J. L., Ma, X., Zafonte, R. D. & Dixon, C. E. Bromocriptine reduces lipid peroxidation and enhances spatial learning and hippocampal neuron survival in a rodent model of focal brain trauma. *Journal of Neurotrauma* **21**, 1712–1722 (2004).

75. Chen, K., Gunter, K. & Maines, M. D. Neurons overexpressing heme oxygenase-1 resist oxidative stress-mediated cell death. *Journal of Neuroscience Research* **75**, 304–313 (2000).

76. Mancuso, C. Heme oxygenase and its products in the nervous system. *Antioxidants & Redox Signaling* **6**, 878–887 (2004).

77. Barone, E. et al. Basal brain oxidative and nitrite stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53. *Journal of Neurochemistry* **93**, 1728–1739 (2015).

78. Langeveld, C. H. et al. Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development. *Neurosci Lett* **192**, 13–16 (1995).

79. O’Callaghan, J. P., Sriram, K. & Miller, D. B. Defining “neuroinflammation”. *FASEB Journal: official publication of the Federation of American Societies for Experimental Biology* **19**, 97–106 (2005).

80. Woodcock, T. & Morganti-Kossmann, M. C. The role of markers of inflammation in traumatic brain injury. *Front Neurol* **4**, 18 (2013).

81. Potucek, Y. D., Crain, J. M. & Watts, J. J. Purinergic receptors modulate MAP kinases and transcription factors that control microglial inflammatory gene expression. *Neurochem Int* **49**, 204–214 (2006).

82. Rock, R. B. & Peterson, P. K. Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. *J Neuroimmun Pharmacol* **1**, 117–126 (2006).

83. Chen, C. J. et al. Glial activation involvement in neuronal death by Japanese encephalitis virus infection. *J Gen Virol* **91**, 1028–1037 (2010).

84. Li, L., Yan, J., Miao, Y., Lei, P. & Zhang, Q. ROS and Autophagy: Interactions and Molecular Regulatory Mechanisms. *Cell Mol Neurobiol* (2015).

85. Smith, C. M., Chen, Y., Sullivan, M. L., Kochanek, P. M. & Clark, R. S. Autophagy in acute brain injury: feast, famine, or folly? *Neurobiology of Disease* **43**, 52–59 (2011).

86. Clark, R. S. et al. Autophagy is increased in mice after traumatic brain injury and is detectable in human brain after trauma and critical illness. *Autophagy* **4**, 88–90 (2008).

87. Kabeya, Y. et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *The EMBO Journal* **19**(2000).

88. Mizushima, N., Yoshimori, T. & Ohsumi, Y. The role of Atg proteins in autophagosome formation. *Annual Review of Cell and Developmental Biology* **27**, 107–132 (2011).

89. Ichimura, Y. et al. Structural basis for sorting mechanism of p62 in selective autophagy. *The Journal of biological chemistry* **283**, 22847–22857 (2008).

90. Raghupathi, R., Graham, D. I. & McIntosh, T. K. Apoptosis after traumatic brain injury. *Journal of Neurotrauma* **17**, 927–938 (2000).

91. Hoagland, J. M., Hoagland, E. M. & Swanson, H. I. The p53 inhibitor pifithrin-alpha is a potent agonist of the aryl hydrocarbon receptor. *The Journal of Pharmacology and Experimental Therapeutics* **314**, 603–610 (2005).

92. Sparfel, L., Van Grevenynghe, J., Le Vee, M., Aninat, C. & Fardel, O. Potent inhibition of carcinogen-bioactivating cytochrome P450 1B1 by the p53 inhibitor pifithrin alpha. *Carcinogenesis* **27**, 656–663 (2006).

93. Komarova, E. A. et al. p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. *The Journal of Biological Chemistry* **278**, 15465–15468 (2003).

94. Murphy, P. J. et al. Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its cellular translocation. *The Journal of Biological Chemistry* **279**, 30195–30201 (2004).

95. Wang, I. Y. et al. Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. *Journal of Neuroinflammation* **13**, 168 (2016).

96. Chen, S. F. et al. Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. *Life Sci* **81**, 288–298 (2007).

97. Pfeffer, M., Gonzalez, A. & Law, W. A. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. *Science* **217**, 855–857 (1982).

98. Chen, S. F., Hsu, C. W., Huang, W. H. & Wang, J. Y. Post-injury baiacine improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury. *British Journal of Pharmacology* **155**, 1279–1296 (2008).

Acknowledgements This work was supported by a grant (MOST104-2923-B-038-001-MY3) to JYW from the Ministry of Science and Technology, Taiwan, and a grant (104-105-175-01011) to YNH from Taipei Medical University, Taiwan.
Author Contributions
Conceived and designed the experiments: Y.N.H., Nigel H. Greig and J.Y.W. Performed the experiments: Y.N.H., L.Y.Y. and Y.C.W. Analyzed the data: Y.N.H., C.C.L. and J.Y.W. Contributed reagents/materials/analysis tools: Y.N.H., C.C.L., and J.Y.W. Wrote the paper: Y.N.H. and J.Y.W. All authors approved the manuscript.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018